Oncology hematology health care professionals from Memorial Sloan Kettering Cancer Center react to the variation in symptoms that patients suspicious of chronic lymphocytic leukemia present with.

An overview of tests used to evaluate patients for chronic lymphocytic leukemia and, consequently, inform treatment decisions.

Staging criteria used in the diagnosis of chronic lymphocytic leukemia, and recommendations for talking with patients about molecular testing results and goals of therapy.

Oncology hematology health care professionals from Memorial Sloan Kettering Cancer Center discuss how to manage a 67-year-old woman with chronic lymphocytic leukemia who develops progressive fatigue and night sweats.

Recommendations for using novel targeted therapies to treat chronic lymphocytic leukemia in the frontline setting.

Common toxicities associated with novel targeted therapies, such as BTK inhibitors, used to treat chronic lymphocytic leukemia, and recommendations on how to manage with dose adjustments.

The importance of multidisciplinary care in chronic lymphocytic leukemia and proper patient education on adverse events associated with novel targeted therapies.

Reactions to an atypical diagnosis of high-risk chronic lymphocytic leukemia in a 61-year-old man.

Frontline therapies available to treat newly diagnosed high-risk chronic lymphocytic leukemia, and the rationale for selecting a targeted therapy versus chemoimmunotherapy as initial treatment.

The rationale for integrating CD20 monoclonal antibody therapy into the frontline setting of chronic lymphocytic leukemia.

Susan O’Brien, MD, and Anthony Mato, MD, MSCE, describe their preferences for treating newly diagnosed chronic lymphocytic leukemia based on disease presentation and patient variables.

The rationale for investigating and using PI3K inhibitors to treat chronic lymphocytic leukemia.

Implications for treating chronic lymphocytic leukemia with small molecule combination regimens in the frontline setting.

Exciting novel-based treatment strategies being investigated in chronic lymphocytic leukemia.